AU1537292A
(en)
*
|
1991-04-16 |
1992-11-17 |
Nippon Shinyaku Co. Ltd. |
Method of manufacturing solid dispersion
|
DE69222182T2
(de)
|
1991-12-18 |
1998-02-26 |
Warner Lambert Co |
Verfahren für die herstellung einer festen dispersion
|
EP0729748B1
(de)
*
|
1993-11-18 |
2003-02-26 |
Nippon Shinyaku Company, Limited |
Verfahren zur herstellung stabiler arzneimittel
|
SE9502244D0
(sv)
*
|
1995-06-20 |
1995-06-20 |
Bioglan Ab |
A composition and a process for the preparation thereof
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
ATE427124T1
(de)
|
1996-06-26 |
2009-04-15 |
Univ Texas |
Heiss-geschmolzene extrudierbare pharmazeutische formulierung
|
ATE273002T1
(de)
*
|
1996-06-28 |
2004-08-15 |
Schering Corp |
Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
US6107341A
(en)
*
|
1997-12-19 |
2000-08-22 |
Bissell Homecare, Inc. |
Aqueous miticide containing benzyl benzoate
|
US6376542B1
(en)
*
|
1997-12-19 |
2002-04-23 |
Bissell Homecare, Inc. |
Aqueous miticide compositions containing benzyl benzoate
|
DE69821984T2
(de)
*
|
1997-12-22 |
2004-12-30 |
Schering Corp. |
Zubereitung enthaltend eine molekulardispersion mit erhöhter bioverfügbarkeit
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
DE19913606A1
(de)
*
|
1999-03-25 |
2000-09-28 |
Basf Ag |
Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
MXPA01012225A
(es)
*
|
1999-05-28 |
2002-08-12 |
Abbott Lab |
Formulaciones novedosas que comprenden agentes reguladores de lipido.
|
DE19929361A1
(de)
*
|
1999-06-25 |
2001-01-04 |
Basf Ag |
Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
|
JP5767429B2
(ja)
*
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
DE10000792A1
(de)
*
|
2000-01-11 |
2001-07-19 |
Bernhard C Lippold |
Formulierungen von Wirkstoffen in Form einer festen Dispersion
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
BR0210518A
(pt)
|
2001-06-22 |
2004-06-22 |
Pfizer Prod Inc |
Composições farmacêuticas de dispersões de drogas e polìmeros neutros
|
CA2450762A1
(en)
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
|
EP1469832B2
(de)
*
|
2002-02-01 |
2016-10-26 |
Bend Research, Inc. |
Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
|
MY140561A
(en)
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
GB0205253D0
(en)
*
|
2002-03-06 |
2002-04-17 |
Univ Gent |
Immediate release pharmaceutical granule compositions and a continuous process for making them
|
EP1482946A1
(de)
*
|
2002-03-14 |
2004-12-08 |
Watson Pharmaceuticals, Inc. |
Progesteronhaltiges oral anzuwendendes wirkstoffabgabesystem
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
KR20050045946A
(ko)
|
2002-06-25 |
2005-05-17 |
애크럭스 디디에스 피티와이 리미티드 |
비정질 약학적 조성물을 이용한 경피전달속도의 제어
|
JP2006518380A
(ja)
|
2003-01-31 |
2006-08-10 |
スミスクライン・ビーチャム・コーポレイション |
固体分散体組成物
|
CN101091695B
(zh)
*
|
2003-02-03 |
2011-01-19 |
诺瓦提斯公司 |
药物制剂
|
ME00524B
(me)
|
2003-03-10 |
2011-10-10 |
Astrazeneca Ab |
Novi postupak za dobijanje roflumilasta
|
CA2523883C
(en)
*
|
2003-04-29 |
2012-01-03 |
Akzo Nobel N.V. |
Antisolvent solidification process
|
PE20050150A1
(es)
*
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
CL2004000983A1
(es)
*
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
US8273371B2
(en)
|
2003-06-27 |
2012-09-25 |
Johan Adriaan Martens |
Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
|
GB0315012D0
(en)
*
|
2003-06-27 |
2003-07-30 |
Leuven K U Res & Dev |
Zeotiles
|
CA2532931A1
(en)
*
|
2003-08-04 |
2005-02-10 |
Pfizer Products Inc. |
Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
JP5069001B2
(ja)
|
2003-10-10 |
2012-11-07 |
ベロクシス ファーマシューティカルズ エー/エス |
フィブラートを含む固体投与形態
|
SI1691787T1
(sl)
*
|
2003-12-04 |
2008-10-31 |
Pfizer Prod Inc |
Postopek za pripravo farmacevtskih produktov iz več delcev
|
KR100629771B1
(ko)
*
|
2004-01-27 |
2006-09-28 |
씨제이 주식회사 |
결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
CA2601250C
(en)
*
|
2005-03-16 |
2014-10-28 |
Nycomed Gmbh |
Taste masked dosage form containing roflumilast
|
WO2006112649A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Ctc Bio, Inc. |
Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
|
KR100627687B1
(ko)
*
|
2005-04-20 |
2006-09-25 |
주식회사 씨티씨바이오 |
시부트라민 유리염기 함유 조성물 및 이의 제조방법
|
DE102005023803A1
(de)
*
|
2005-05-19 |
2006-11-23 |
Basf Ag |
Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
|
KR20070025070A
(ko)
*
|
2005-08-31 |
2007-03-08 |
주식회사 대웅제약 |
시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
|
GB0612695D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Gent |
Process for preparing a solid dosage form
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US20080132560A1
(en)
*
|
2006-11-21 |
2008-06-05 |
San-Laung Chow |
Solid dispersion composition
|
WO2008079629A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Boehringer Ingelheim International Gmbh |
Formulations with improved bioavailability
|
AP2010005341A0
(en)
*
|
2008-01-11 |
2010-08-31 |
Cipla Ltd |
Solid pharmaceutical dosage form
|
BRPI0906467C1
(pt)
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
KR101690094B1
(ko)
|
2008-05-09 |
2016-12-27 |
그뤼넨탈 게엠베하 |
분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
|
PE20121067A1
(es)
|
2009-07-22 |
2012-09-05 |
Gruenenthal Chemie |
Forma de dosificacion de liberacion controlada extruida por fusion en caliente
|
WO2011009604A1
(en)
|
2009-07-22 |
2011-01-27 |
Grünenthal GmbH |
Oxidation-stabilized tamper-resistant dosage form
|
JP6211768B2
(ja)
*
|
2009-10-27 |
2017-10-11 |
ルピン・リミテッド |
リファキシミンの固溶体
|
WO2012028319A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising inorganic salt
|
CA2808541C
(en)
|
2010-09-02 |
2019-01-08 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising an anionic polymer
|
CN103179959A
(zh)
|
2010-10-20 |
2013-06-26 |
帝斯曼知识产权资产管理有限公司 |
含悬挂亲水基的可生物降解的组合物和相关器械
|
CA3152557A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
AR087360A1
(es)
|
2011-07-29 |
2014-03-19 |
Gruenenthal Gmbh |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
KR20140053158A
(ko)
|
2011-07-29 |
2014-05-07 |
그뤼넨탈 게엠베하 |
즉시 약물 방출을 제공하는 탬퍼-저항성 정제
|
WO2013030789A1
(en)
|
2011-08-30 |
2013-03-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
|
CA2864949A1
(en)
|
2012-02-28 |
2013-09-06 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
CA2913209A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper resistant dosage form with bimodal release profile
|
EP3003279A1
(de)
|
2013-05-29 |
2016-04-13 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit einem oder mehreren partikeln
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
MX371372B
(es)
|
2013-11-26 |
2020-01-28 |
Gruenenthal Gmbh |
Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
WO2015181059A1
(en)
|
2014-05-26 |
2015-12-03 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
EP3227299B1
(de)
*
|
2014-12-04 |
2021-05-26 |
Merck Sharp & Dohme Corp. |
Formulierung zur hemmung der effekte einer schwach sauren umgebung
|
JP2018517676A
(ja)
|
2015-04-24 |
2018-07-05 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時放出および溶媒抽出に対する耐性を有する改変防止製剤
|
WO2017042325A1
(en)
|
2015-09-10 |
2017-03-16 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
CN113616599B
(zh)
*
|
2021-09-10 |
2022-11-18 |
宁夏医科大学 |
一种大黄素固体分散体及其制备方法与应用
|